A recent study utilizing the FDA Adverse Reaction Reporting System (Satoh et al., 2024) revealed that PD-1 inhibitors represent the predominant immunotherapies associated with the induction of SJS/TEN induction.(58.9%), followed by PD-1 inhibitors combined with CTLA-4 inhibitors (11.6%). Here, CTLA4 is linked to toxic epidermal necrolysis.